Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rx Labeling Final Rule Largely In Line With Draft Version

This article was originally published in The Pink Sheet Daily

Executive Summary

New labeling format will apply initially to recently approved drugs and products receiving approval for new uses, agency says.

You may also be interested in...

US FDA References Off-Label Use In Otherwise Bland Labeling Draft Guidance

Product labels can be required to have warnings related to commonly prescribed unapproved uses with significant safety risks.

Pregnancy Labeling Changes May Spur Research, FDA Says

Final regulation eliminates use of letter-based categories to designate level of risk during pregnancy and lactation; in a change from the 2008 proposed rule, information relevant to drug effects on reproductive potential will now be housed in dedicated section.

FDA’s Label Conversion Project Would Revise Data As Well As Reformat

Solicitation asks for contractor to reformat labels to physician labeling rule format, including updates with new information from literature; generic companies like contractor, while brands say it will be resource-intensive for industry and FDA.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts